Navigation Links
Anti-cancer gene discovered: Perspective for therapy
Date:2/24/2009

Starting with the tiny fruit fly, and then moving into mouse and human patients, researchers at VIB connected to the Center for Human Genetics (K.U. Leuven) showed that the same gene suppresses cancer in all three. Reciprocally, switching off the gene leads to cancer. The scientists think there is a good chance that the gene can be switched on again with a drug. They report their findings in the reputed scientific journal PLoS Biology.

Specialized cells

All of us begin our lives as one cell, which divides into two, four, eight into a human of a few billion cells. Almost all cells in an adult human skin cells, liver cells, eye lens cells, nerve cells, insulin-producing cells etc are highly specialized to perform a specific function. They are no longer capable of taking on another task: when a skin cell divides, you get more skin cells. During the growth from an embryo to an adult human, the cells become more and more specialized ("differentiated", biologists say).

Cancer cells are an exception to that rule: they are much less specialized, and feel at home in different places in the body. Researchers have long believed that cells must take the last step in their specialization to be better protected from turning into cancer cells. However, this was not proven in a living organism.

Suppressing cancer

Wouter Bossuyt from the Group of Bassem Hassan and their fellow VIB researchers at K.U.Leuven, now demonstrate with fruit flies that master control genes steering the specialization step indeed inhibit tumor formation. The specific example the VIB scientists used, are the ones biologists call the Atonal genes. These genes are very similar to each other in all species, from flies to humans.

With mice, and in collaboration with colleagues from the United States, they showed that loss of one of those genes, Atonal homolog 1 or ATOH1, causes colon cancer. The gene regulates the last step in the specialization to epithelial cell of the colon. Humans with colon cancer frequently have an inactivated ATOH1 gene, the researchers observed.

Treatment

The researchers could in a test tube reactivate the gene in human colon cancer cells. The tumor cells stopped growing and committed suicide. Since they were able to switch the gene on with a reasonably simple chemical, this opens possibilities to one day perhaps switch the gene back on in living patients. It will be very important in the future to study in detail how exactly ATOH1 does performs its anti-cancer job


'/>"/>

Contact: Sooike Stoops
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology technology :

1. FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
2. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
3. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
4. Computer predicts anti-cancer molecules
5. AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs
6. ARIUS presents new findings for anti-cancer antibody programs at AACR
7. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
8. Vaccinogens New Anti-Cancer Vaccine Commercially Available in Europe This Year
9. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
10. Egenix Licenses Harvard Anti-Cancer Platform
11. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 ... ... announces publication of a United States multicenter, prospective clinical study that demonstrates ... point-of-care diagnostic test capable of identifying clinically significant acute bacterial and viral ...
(Date:10/12/2017)... ... 12, 2017 , ... AMRI, a global contract research, development ... patient outcomes and quality of life, will now be offering its impurity solutions ... new regulatory requirements for all new drug products, including the finalization of ICH ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board ... Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced ... for membership in ARCS Alumni Hall of Fame . ASTER Labs is ...
(Date:10/11/2017)... ... 2017 , ... Personal eye wash is a basic first aid supply for any work environment, ... eye do you rinse first if a dangerous substance enters both eyes? It’s one less ... with its unique dual eye piece. , “Whether its dirt and debris, or an acid ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):